Loading...
Market
Will major insurance companies start covering GLP-1 drugs for cancer risk reduction in Type 2 diabetes patients by the end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from major insurance companies
Story
Study Finds Ozempic, Wegovy Lower Cancer Risk in Type 2 Diabetes Patients by 10 out of 13
Jul 5, 2024, 05:09 PM
A new study has found that GLP-1 drugs, including Ozempic and Wegovy, significantly reduce the risk of cancer in patients with type 2 diabetes. The retrospective cohort study, which analyzed electronic health records of approximately 1.65 million people over 15 years, revealed that patients on GLP-1 medications had a lower risk for 10 out of 13 obesity-related cancers compared to those on insulin therapy. The findings, published Friday in JAMA Network Open, were based on data from 113 million US patients and suggest a promising alternative for reducing cancer risk in diabetic patients.
View original story
Similar markets
Zepbound • 25%
Wegovy • 25%
Ozempic • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
None • 25%
1 company • 25%
2 companies • 25%
3 or more companies • 25%
Yes • 50%
No • 50%
Significant improvement in affordability perception • 25%
Slight improvement in affordability perception • 25%
No change in affordability perception • 25%
Worsening perception of affordability • 25%
Coverage for both Ozempic and Wegovy • 25%
Coverage for Ozempic only • 25%
Coverage for Wegovy only • 25%
No coverage expansion • 25%
